Maxim starts Mainz Biomed at Buy on CRC screening potential

As previously reported, Maxim initiated coverage of Mainz Biomed (MYNZ) with a Buy rating and $14 price target The firm is positive on the company’s position as an emerging player in the $4B colorectal cancer – CRC – screening market with at-home, fecal-based, testing kits, noting that its Next Generation Test leverages mRNA biomarkers to expand the ability to detect pre-cancerous advanced adenomas while enabling prevention of CRC, the analyst tells investors in a research note. Maxim further cites Mainz’s ongoing clinical study – eAArly DETECT 2 – with data expected in the second half of 2025.